Literature DB >> 10786690

The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched.

C Wetmore1, D E Eberhart, T Curran.   

Abstract

Defects in a developmental signaling pathway involving mammalian homologues of the Drosophila segment polarity gene, patched (ptc) and its ligand, sonic hedgehog (shh), contribute to tumor formation in several tissues. Recently, a subset of medulloblastoma, the most common malignant brain tumor in children, was found to contain somatic mutations in the human ptc gene. In addition, basal cell nevus syndrome (BCNS), or Gorlin syndrome, which is characterized by developmental anomalies and a predisposition to skin and nervous system malignancies, is associated with germ-line mutation of ptc. Targeted disruption of both alleles of ptc in mice results in embryonic lethality. However, ptc+/- mice survive and develop spontaneous cerebellar brain tumors, suggesting that ptc may function as a tumor suppressor gene. Therefore, we investigated ptc+/-mice as a model for human medulloblastoma. We report that 14% of ptc+/- mice develop central nervous system tumors in the posterior fossa by 10 months of age, with peak tumor incidence occurring between 16 and 24 weeks of age. The tumors exhibited several characteristics of human medulloblastoma, including expression of intermediate filament proteins specific for neurons and glia. Full-length ptc mRNA was present in all tumors analyzed, indicating that there was no loss of heterozygosity at the ptc locus. Nucleotide sequence of ptc mRNA from four tumors failed to identify any mutations. However, a comparison of the normal ptc sequence from C57BL/6 and 129Sv mice did reveal several polymorphisms. High levels of glil mRNA and protein were detected in the tumors, suggesting that the shh/ptc pathway was activated despite the persistence of ptc expression. These data indicate that haploinsufficiency of ptc is sufficient to promote oncogenesis in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10786690

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  58 in total

1.  Medulloblastoma in mice lacking p53 and PARP: all roads lead to Gli.

Authors:  Charles G Eberhart
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

Review 2.  Medulloblastoma-biology and microenvironment: a review.

Authors:  Tiara Byrd; Robert G Grossman; Nabil Ahmed
Journal:  Pediatr Hematol Oncol       Date:  2012-06-28       Impact factor: 1.969

3.  DDX3X Suppresses the Susceptibility of Hindbrain Lineages to Medulloblastoma.

Authors:  Deanna M Patmore; Amir Jassim; Erica Nathan; Reuben J Gilbertson; Daniel Tahan; Nadin Hoffmann; Yiai Tong; Kyle S Smith; Thirumala-Devi Kanneganti; Hiromichi Suzuki; Michael D Taylor; Paul Northcott; Richard J Gilbertson
Journal:  Dev Cell       Date:  2020-06-17       Impact factor: 12.270

4.  Loss of cyclin D1 impairs cerebellar development and suppresses medulloblastoma formation.

Authors:  Jennifer Pogoriler; Kathleen Millen; Manuel Utset; Wei Du
Journal:  Development       Date:  2006-08-30       Impact factor: 6.868

5.  Neuron-to-astrocyte transition: phenotypic fluidity and the formation of hybrid asterons in differentiating neurospheres.

Authors:  Eric D Laywell; Sean M Kearns; Tong Zheng; K Amy Chen; Jie Deng; Huan-Xin Chen; Steven N Roper; Dennis A Steindler
Journal:  J Comp Neurol       Date:  2005-12-19       Impact factor: 3.215

Review 6.  Matching mice to malignancy: molecular subgroups and models of medulloblastoma.

Authors:  Jasmine Lau; Christin Schmidt; Shirley L Markant; Michael D Taylor; Robert J Wechsler-Reya; William A Weiss
Journal:  Childs Nerv Syst       Date:  2012-04       Impact factor: 1.475

7.  N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma.

Authors:  Jessica D Kessler; Hiroshi Hasegawa; Sonja N Brun; Brian A Emmenegger; Zeng-Jie Yang; John W Dutton; Fan Wang; Robert J Wechsler-Reya
Journal:  Genes Dev       Date:  2009-01-15       Impact factor: 11.361

8.  Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.

Authors:  Xue Qing Lun; Hongyuan Zhou; Tommy Alain; Beichen Sun; Limei Wang; John W Barrett; Marianne M Stanford; Grant McFadden; John Bell; Donna L Senger; Peter A Forsyth
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

Review 9.  Medulloblastoma: molecular genetics and animal models.

Authors:  Corey Raffel
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

Review 10.  Translating cyclooxygenase signaling in patch heterozygote mice into a randomized clinical trial in basal cell carcinoma.

Authors:  Jack L Arbiser
Journal:  Cancer Prev Res (Phila)       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.